Restitutio ad integrum

Record sales and profitability: Integrum AB

Retrieved on: 
Monday, December 4, 2023
Restitutio ad integrum, Food, Elective surgery, Unitary patent, SEK, US Foods, Risk, Patient, Mercedes-Benz Axor, FDA, Marketing, USD, Ryan AbilityLab, CMS, NIH, Trauma, Trial of the century, Amputation, Growth, Medicare, Bangladesh Technical Education Board, PMA, Patent, Life insurance, Cryptocurrency, Health insurance, Medical device, Pharmaceutical industry, Application

The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.

Key Points: 
  • The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.
  • Our second quarter has been intense with record sales, increased operating profit and a number of great achievements that will help drive the business forward.
  • During the quarter, Integrum made a restructuring of the company´s sales and marketing organization to fully focus on executing growth in the US.
  • At the end of October, Integrum signed a distribution agreement for the Turkish market which generated sales of 1.3 MSEK.

Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023

Retrieved on: 
Friday, November 10, 2023
Disclosure, Restitutio ad integrum, Q2, MAR

MÖLNDAL, Sweden, Nov. 10, 2023 /PRNewswire/ -- For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added.

Key Points: 
  • MÖLNDAL, Sweden, Nov. 10, 2023 /PRNewswire/ -- For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added.
  • Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.
  • The complete result for Integrum will be presented in the quarterly report for August - October 2023 which is published on December 4, 2023.
  • This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

Integrum's OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations

Retrieved on: 
Monday, October 30, 2023
FDA, Walter Reed National Military Medical Center, Trial of the century, Amputation, Restitutio ad integrum, Medical device

MÖLNDAL, Sweden, Oct. 30, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company's OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US.

Key Points: 
  • MÖLNDAL, Sweden, Oct. 30, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company's OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US.
  • The clinical study will be important for the future approval of the OPRA™ Implant System on the below-knee amputation level, which is the most frequent amputation level.
  • The study will be performed by the Walter Reed National Military Medical Center.
  • "This is an important milestone in the expansion of indications for our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.

Integrum moves into Turkey

Retrieved on: 
Friday, October 27, 2023
Amputation, Quality of life, Restitutio ad integrum, Medical device

MÖLNDAL, Sweden, Oct. 27, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.

Key Points: 
  • MÖLNDAL, Sweden, Oct. 27, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.
  • As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today started a collaboration in Turkey with Medikon ( www.medikon.net ).
  • "The collaboration with Medikon secures a foothold in the Turkish market for Integrum's unique solutions, a country where orthopedic healthcare is strongly marked by the earthquake that occurred earlier this year.
  • There is a great need for innovative orthopedic solutions, and we are happy to be able to help improve the quality of life for amputees with our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.

Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth

Retrieved on: 
Friday, August 18, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Medication, VisionAire 500K, Growth, Spacecraft, HKEX, 1998 Pep Boys 400K, IND, Investment, Antibody, Restitutio ad integrum, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
  • Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets.
  • The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies.
  • As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.

Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth

Retrieved on: 
Thursday, August 17, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Medication, Growth, Spacecraft, HKEX, IND, Investment, Antibody, Restitutio ad integrum, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
  • Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets.
  • The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies.
  • As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.

Integrum Marks 25 Years of Innovation and Improving Quality of Life for Individuals With Amputations

Retrieved on: 
Wednesday, July 19, 2023
Maintenance, University, Dental implant, CE marking, University of California, San Francisco, Osseointegration, Research, Brain, Sympathetic nervous system, Electrode, Professor, Hospital, Prosthesis, Patient, Restitutio ad integrum, FDA, NIH, Amputation, Medical device

Since then, Integrum has helped improve the lives of hundreds of people by allowing them to have a more active lifestyle.

Key Points: 
  • Since then, Integrum has helped improve the lives of hundreds of people by allowing them to have a more active lifestyle.
  • Initially, it was used for dental implants (and dental implants are still a major indication), but it was later adapted for prosthetic limbs.
  • In 1998, Per-Ingvar's son Dr Rickard Brånemark founded Integrum, specializing in artificial limb technology attached using osseointegration techniques.
  • This is much more than a business opportunity – this is, by far, the biggest-ever change in amputee care!,” Brånemark says.

Integrum Worldwide Retains DAC Capital as Exclusive Buy-side Advisor

Retrieved on: 
Wednesday, March 15, 2023
Acquisition, FINRA, New York University Stern School of Business, LOS, Business, Apollo Global Management, Software, DAC, Capital market, PALAZZO, MBA, Advertising, Rensselaer Polytechnic Institute, Restitutio ad integrum, Information services, Financial services

LOS ANGELES, March 15, 2023 /PRNewswire/ -- Integrum Worldwide, the global marketing agency collective backed by Apollo Management and M2B Growth Enterprises, today announced that DAC Capital has been retained as Integrum's exclusive buy-side advisory firm. Led by David Abraham, DAC Capital will support Integrum, as well as its two agencies Storia and Chalk, as the collective continues making strategic acquisitions in various marketing service areas.

Key Points: 
  • LOS ANGELES, March 15, 2023 /PRNewswire/ -- Integrum Worldwide , the global marketing agency collective backed by Apollo Management and M2B Growth Enterprises, today announced that DAC Capital has been retained as Integrum's exclusive buy-side advisory firm.
  • Led by David Abraham, DAC Capital will support Integrum, as well as its two agencies Storia and Chalk , as the collective continues making strategic acquisitions in various marketing service areas.
  • Abraham, DAC Capital's principal, has completed transactions including acquisitions, asset sales, financings throughout the capital structure, restructurings and work-outs, and other corporate financial activities.
  • "I've worked with David and his firm DAC Capital in various capacities over the years and I'm excited to be able to bring him on-board to help us continue to scale at Integrum Worldwide," said Claude Zdanow, Integrum Worldwide's President.

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

Retrieved on: 
Monday, December 19, 2022
FDA, Health, Clinical Trials, Research, Science, Biotechnology, Neutralizing antibody, Lymphatic system, DC, Patient, Tumor microenvironment, Neoplasm, Toxicology, US, Liver, CD40, Medication, FDA, Safety, Multinational corporation, HKEX, CSO, Mouse, Immunoglobulin G, Restitutio ad integrum, Investigational New Drug, GLP, IND, CMO, Monoclonal antibody, Syngenic, Pharmacokinetics, Research, Pharmaceutical industry, Medical imaging

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb).
  • The IND application was completed by Biocytogen’s wholly owned subsidiary Eucure Biopharma.
  • YH008101) that will evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH008 monotherapy in patients with PD-(L)1-resistant advanced solid tumors or hematological malignancies.
  • Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum.

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

Retrieved on: 
Monday, December 19, 2022
Oncology, Health, FDA, Research, Science, Pharmaceutical, Biotechnology, Restitutio ad integrum, Liver, Investigational New Drug, CMO, GLP, Tumor microenvironment, Monoclonal antibody, Lymphatic system, Neoplasm, FDA, US, Safety, Neutralizing antibody, Pharmacokinetics, Immunoglobulin G, DC, HKEX, Toxicology, Medication, CSO, CD40, Syngenic, Research, IND, Multinational corporation, Patient, Pharmaceutical industry, Medical imaging

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb).
  • The IND application was completed by Biocytogen’s wholly owned subsidiary Eucure Biopharma.
  • YH008101) that will evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH008 monotherapy in patients with PD-(L)1-resistant advanced solid tumors or hematological malignancies.
  • Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum .